A Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, PD, PK, and clinical activity of AB680 in combination with zimberelimab, nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.
Key Eligibility Criteria
- Histologically or cytologically confirmed metastatic pancreatic adenocarcinoma
- Naive to any prior treatment, including chemotherapy, biological therapy, or targeted therapy for metastatic disease
- Prior adjuvant therapy (including chemotherapy and/or radiotherapy) for pancreatic adenocarcinoma is permitted if neoadjuvant or adjuvant therapy was completed at least 6 months prior to trial enrollment. Prior adjuvant therapy may include nab-paclitaxel or gemcitabine
- Participants initially diagnosed with locally advanced pancreatic cancer who have undergone chemotherapy then resection and had no evidence of disease are eligible if relapse of metastatic disease has occurred and if the last dose of chemotherapy was received more than 6 months before trial entry